Literature DB >> 19220726

The CYP2C19*2 and CYP2C19*3 polymorphisms are associated with high post-treatment platelet reactivity in Asian patients with acute coronary syndrome.

I-S Kim, B-R Choi, Y-H Jeong, C H Kwak, S Kim.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19220726     DOI： 10.1111/j.1538-7836.2009.03319.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN： 1538-7836            Impact factor:   5.824


× No keyword cloud information.
  14 in total

1.  Correlation of high post-treatment platelet reactivity assessed by light transmittance aggregometry and the VerifyNow P2Y12 assay.

Authors:  In-Suk Kim; Young-Hoon Jeong; Min-Kyung Kang; Jin-Sin Koh; Yongwhi Park; Seok-Jae Hwang; Choong Hwan Kwak; Jin-Yong Hwang; Sunjoo Kim
Journal:  J Thromb Thrombolysis       Date:  2010-11       Impact factor: 2.300

Review 2.  Pharmacogenetics of CYP2C19: functional and clinical implications of a new variant CYP2C19*17.

Authors:  Alain Li-Wan-Po; Thierry Girard; Peter Farndon; Candy Cooley; James Lithgow
Journal:  Br J Clin Pharmacol       Date:  2010-03       Impact factor: 4.335

3.  Interaction analysis between genetic polymorphisms and pharmacodynamic effect in patients treated with adjunctive cilostazol to dual antiplatelet therapy: results of the ACCEL-TRIPLE (Accelerated Platelet Inhibition by Triple Antiplatelet Therapy According to Gene Polymorphism) study.

Authors:  In-Suk Kim; Young-Hoon Jeong; Yongwhi Park; Seong-Eun Yoon; Tae Jung Kwon; Jeong Rang Park; Seok-Jae Hwang; Eun-Ha Koh; Choong Hwan Kwak; Jin-Yong Hwang; Sunjoo Kim
Journal:  Br J Clin Pharmacol       Date:  2012-04       Impact factor: 4.335

Review 4.  Expert consensus document: World Heart Federation expert consensus statement on antiplatelet therapy in East Asian patients with ACS or undergoing PCI.

Authors:  Glenn N Levine; Young-Hoon Jeong; Shinya Goto; Jeffrey L Anderson; Yong Huo; Jessica L Mega; Kathryn Taubert; Sidney C Smith
Journal:  Nat Rev Cardiol       Date:  2014-08-26       Impact factor: 32.419

5.  Ticagrelor versus genotype-driven antiplatelet therapy for secondary prevention after acute coronary syndrome: a cost-effectiveness analysis.

Authors:  Daniel J Crespin; Jerome J Federspiel; Andrea K Biddle; Daniel E Jonas; Joseph S Rossi
Journal:  Value Health       Date:  2011-05-19       Impact factor: 5.725

6.  An algorithm for use of prasugrel (effient) in patients undergoing cardiac catheterization and percutaneous coronary intervention.

Authors:  Julio Marchini; David Morrow; Frederic Resnic; Andre Manica; James Kirshenbaum; Christopher Cannon; Kevin Croce
Journal:  Crit Pathw Cardiol       Date:  2010-12

7.  Cytochrome P450 2C19 polymorphism is associated with reduced clopidogrel response in cerebrovascular disease.

Authors:  Jun-Beom Lee; Kyung-A Lee; Kyung-Yul Lee
Journal:  Yonsei Med J       Date:  2011-09       Impact factor: 2.759

8.  Genetic testing for CYP450 polymorphisms to predict response to clopidogrel: current evidence and test availability. Application: pharmacogenomics.

Authors:  Renée M Ned Mmsc Phd
Journal:  PLoS Curr       Date:  2010-09-20

9.  Antiplatelet effect of clopidogrel can be reduced by calcium-channel blockers.

Authors:  Kwon-Duk Seo; Young Dae Kim; Young-Won Yoon; Jong-Youn Kim; Kyung-Yul Lee
Journal:  Yonsei Med J       Date:  2014-04-01       Impact factor: 2.759

10.  Association between genetic polymorphisms of cytochrome P450 2C19 and the risk of cerebral ischemic stroke in Chinese.

Authors:  Shuzhen Gu; Yan Sun; Ruifa Han; Lin Wang; Dongliang Wang; Jizuo Wang; Xin Li
Journal:  BMC Med Genet       Date:  2014-07-17       Impact factor: 2.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.